Tirzepatide + LNG-IUD combination therapy investigated for fertility-sparing endometrial cancer treatment in obese women
Background
The incidence of endometrial cancer is rapidly increasing, mirroring the rise in obesity, its most significant risk factor. Young, obese women seeking to preserve fertility often receive progestin therapy, such as a levonorgestrel intra-uterine device (LNG-IUD). However, this approach has a mediocre response rate and high recurrence, failing to address the underlying obesity. There's a critical need for more effective, fertility-sparing treatments that also tackle metabolic dysfunction.
Study Design
This Phase II clinical trial will evaluate the addition of a weight-loss drug to standard LNG-IUD therapy. The study population includes young women with atypical endometrial hyperplasia or low-grade endometrial cancer who have obesity and desire fertility preservation. Participants will receive tirzepatide injections alongside their LNG-IUD. The primary endpoint is to assess whether this combination improves oncologic, reproductive, and metabolic outcomes, specifically focusing on pathologic response (absence of cancer cells in tissue samples after treatment). The trial is currently 'not yet recruiting'.
Why It Matters
If successful, this trial could revolutionize fertility-sparing treatment for endometrial cancer by integrating a potent weight-loss medication directly into the therapeutic strategy. Current progestin-only approaches often fall short, leaving women with high recurrence rates and unaddressed metabolic issues. Adding tirzepatide could offer a dual benefit: directly impacting cancer progression while simultaneously treating the underlying obesity, a major driver of the disease. This could lead to significantly improved oncologic, reproductive, and metabolic outcomes, offering a more holistic and effective protocol for a vulnerable patient population.
tirzepatide
endometrial-cancer
atypical-hyperplasia
fertility-preservation
obesity
glp-1-agonist